Various targeted complement therapeutics, including anti-C5a monoclonal antibodies, anti-C5 monoclonal antibodies, and C3 inhibitors, have demonstrated promising efficacy in clinical studies for both COVID-19 and sepsis. Here, C5 is linked to COVID-19.